" class="no-js "lang="en-US"> Bryan Federowicz - Medtech Alert
Thursday, September 21, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Bryan Federowicz

Bryan Federowicz

About Bryan Federowicz

Bryan Federowicz works as a Vice President, Clinical Operations at xCures, which is a Healthcare Software company with an estimated 21 employees; and founded in 2018. They are part of the Clinical Operations team within the Medical & Health Department and their management level is VP-Level. Bryan graduated from North Carolina State University in 2013 and is currently based in Durham, United States.

Related Story

Artificial Intelligence

 LifeOmic Deploys AI Solution With xCures to Improve Cancer Research and Treatment | Pharmtech Focus

LifeOmic Deploys AI Solution With xCures to Improve Cancer Research and Treatment

April 29 2022

LifeOmic, a software company that leverages the cloud, machine learning and mobile devices to power […]